Answers are grounded in this paper and cite their sources.
Proform serum calcium-decreasing factor (procaldecrin) was purified from porcine pancreas acetone powder. Procaldecrin showed chymotrypsin activity after trypsin treatment in a time- and dose-dependent manner. Procaldecrin did not possess serum calcium-decreasing activity but acquired serum calcium-decreasing activity as well as protease activity after trypsin treatment. However, PMSF treatment after activation of procaldecrin by trypsin did not affect the serum calcium-decreasing activity, even though protease activity was nullified by treatment with PMSF. These findings suggest that the serum calcium-decreasing activity acquired by procaldecrin requires conformational change caused by trypsin treatment.
No takes yet. Share an insight, caveat, or question.
Tomomura et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: